- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Paroxysmal nocturnal haemoglobinuria (PNH)
- Meeting Date: May 2025
- Public Summary Document (PSD) May 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) May 2025 PBAC Meeting - (Word)
Pegcetacoplan – May 2025
Pegcetacoplan: Solution for subcutaneous infusion 1,080 mg in 20 mL; Empaveli®
Last updated
9 May 2025